Holen Sie sich die Stockscreener-App
62.62
2.08%
-0.50
Handel nachbörslich:
62.62
Schlusskurs vom Vortag:
$63.12
Offen:
$63
24-Stunden-Volumen:
165.03K
Relative Volume:
0.88
Marktkapitalisierung:
$419.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.72M
KGV:
-31.53
EPS:
-1.9861
Netto-Cashflow:
$-12.20M
1W Leistung:
+11.97%
1M Leistung:
+16.18%
6M Leistung:
-29.25%
1J Leistung:
+74.36%
1-Tages-Spanne:
$60.67
$64.17
1-Wochen-Bereich:
$55.00
$65.55
52-Wochen-Spanne:
$28.40
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
62.62 | 422.84M | 0 | -13.72M | -12.20M | -1.9861 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-09 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-08-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
What triggered Monopar Therapeutics shares' latest price pullback - Traders Union
Monopar Therapeutics stock price forecast: Holding $60.25 support as MNPR declines 2.47% - Traders Union
Monopar Therapeutics Q1 2026 Earnings: Narrower Loss Surprises MarketEarnings Outlook Update - Newser
Monopar Therapeutics Presents Positive Phase 2 Results for ALXN1840 in Wilson Disease Patients - Minichart
Monopar reports positive Wilson disease trial data publication By Investing.com - Investing.com South Africa
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data - TipRanks
Monopar reports positive Wilson disease trial data publication - Investing.com India
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease - The Manila Times
Monopar Therapeutics Publishes Phase 2 Trial Results of ALXN1840 for Wilson Disease in Hepatology Communications - Quiver Quantitative
Drug trial helps Wilson disease patients shed excess copper - Stock Titan
ALXN1840 Wilson disease trial data published by Monopar (NASDAQ: MNPR) - Stock Titan
Chardan Capital Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Cuts Target Price to $59.27 - Moomoo
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Saturn V, Xiaoying Tian report 345,626 MNPR shares (5.20%) — MNPR - Stock Titan
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged - TipRanks
A Quick Look at Today's Ratings for Monopar Therapeutics(MNPR.US), With a Forecast Between $104 to $130 - Moomoo
Is Monopar Therapeutics (MNPR) Undervalued After Q1 2026 EPS Bea - GuruFocus
Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Monopar Therapeutics reports Q1 2026 loss, advances ALXN1840 NDA submission for Wilson disease. - Pluang
Monopar Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Monopar (NASDAQ: MNPR) ends Q1 with $137.5M cash and funds through 2027 - Stock Titan
Monopar Therapeutics 1Q 2026: Revenue ($3.93M), Net income ($3.89M), EPS ($0.46) — 10-Q Summary - TradingView
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson Disease - Quiver Quantitative
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics reports Q1 2026 net loss $3.9M, cash $137.5M; NDA on track for mid-2026 - TradingView
Cash runway to 2027 as Monopar (NASDAQ: MNPR) readies ALXN1840 - Stock Titan
Press Release: Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - Moomoo
Monopar Therapeutics stock (US6093601054): Clinical-stage biotech focused on oncology innovations - AD HOC NEWS
Adage (MNPR) reports 424,195 shares, including 115,000 warrant shares - Stock Titan
Monopar Therapeutics stock (US6093601054): Shares up 3% at $65.52 - AD HOC NEWS
TradingKey - TradingKey
The long term thesis for Monopar Therapeutics (MNPR) in plain sight (Smart Money Outflows) 2026-05-08Rising Community Picks - Newser
Behavioral Patterns of MNPR and Institutional Flows - Stock Traders Daily
Number of shareholders of Monopar Therapeutics Inc – MUN:1IY0 - TradingView
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
[ARS] Monopar Therapeutics SEC Filing - Stock Titan
[DEF 14A] Monopar Therapeutics Definitive Proxy Statement - Stock Titan
(MNPR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
MNPR (Monopar Therapeutics Inc.) slips 2.56% after Q4 2025 earnings miss on larger than expected per share loss.ROIC - Xã Thanh Hà
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON) - The Globe and Mail
MNPR Stock Price, Quote & Chart | MONOPAR THERAPEUTICS INC (NASDAQ:MNPR) - ChartMill
Monopar Therapeutics stock maintained at Buy by Lake Street on trial data - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR) and Agios Pharma (AGIO) - The Globe and Mail
Monopar Therapeutics stock maintained at Buy by BTIG on trial data - Investing.com Canada
Monopar Reports Phase 3 Data Showing ALXN1840 Provides Greater Neurologic Benefit Versus Standard of Care in Wilson Disease Patients - Minichart
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification - TipRanks
Monopar Highlights Strong Phase 3 Data for ALXN1840 - TipRanks
Monopar (MNPR) unveils Phase 3 ALXN1840 neurologic gains and plans mid-2026 NDA - Stock Titan
Lake Street Initiates Coverage of Monopar Therapeutics (MNPR) with Buy Recommendation - MSN
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):